MicroRNA-145-3p suppresses proliferation and promotes apotosis and autophagy of osteosarcoma cell by targeting HDAC4
Source abstract
Abstract
Studies have shown that miR-145-3p functions as a tumor suppressor and is associated with tumor growth and metastasis. This study intends to uncover the mechanism of a tumor suppressor of miR-145-3p. The expressions of miR-194 in osteosarcoma cell lines and tissues were monitored by real-time PCR. The proliferation ability was examined by MTT assay. The apoptosis and autophagy of cells were monitored by flow cytometry and microcopy, respectively. The regulation of miR-145-3p on HDAC4 was determined by luciferase assays and western blot assay. The results showed that miR-145-3p was significantly reduced in the osteosarcoma compared with the normal bone tissue. Overexpression of miR-145-3p significantly attenuated the proliferation and induced the apoptosis and autophagy of osteosarcoma cells. Furthermore, we demonstrated that miR-145-3p has inhibited the malignant behavior of osteosarcoma by down-regulating HDAC4 expression. These findings suggested that miR-145-3p may act as a tumor suppressor in osteosarcoma. MiR-145-3p/HDAC4 may be a novel therapeutic target in treatment of osteosarcoma.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: MicroRNA in disease regulation · Histone Deacetylase Inhibitors Research · Epigenetics and DNA Methylation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Hand Surgery, China-Japan Union Hospital, Jilin University, Changchun, China;
Department of Orthopedics, China-Japan Union Hospital, Jilin University, Changchun, China;
Department of Molecular Biology, Medical College, Suchow University, Suzhou, China
References (25)
Show source-provided references
1. 10.1007/978-1-4419-0284-9_110.1007/978-1-4419-0284-9_1 ↗
2. Wu PK · J Clin Oncol · 2009 · 39 · 514
3. 10.1126/science.111144410.1126/science.1111444 ↗
4. 10.1016/j.eururo.2013.11.04610.1016/j.eururo.2013.11.046 ↗
5. 10.1002/biof.2710.1002/biof.27 ↗
6. 10.1016/j.immuni.2007.03.00510.1016/j.immuni.2007.03.005 ↗
7. 10.1186/1471-2407-14-63010.1186/1471-2407-14-630 ↗
8. 10.1016/j.humpath.2014.01.01710.1016/j.humpath.2014.01.017 ↗
9. 10.1371/journal.pone.004490710.1371/journal.pone.0044907 ↗
10. 10.1016/j.jaci.2011.04.00510.1016/j.jaci.2011.04.005 ↗
11. 10.3892/or.2014.359110.3892/or.2014.3591 ↗
12. Zhou X · Int J Clin Exp Med · 2015 · 9 · 16890
13. 10.1002/ijc.2916810.1002/ijc.29168 ↗
14. 10.1038/sj.bjc.660557010.1038/sj.bjc.6605570 ↗
15. 10.3892/ol.2016.546210.3892/ol.2016.5462 ↗
16. 10.1038/cddis.2017.49310.1038/cddis.2017.493 ↗
17. 10.18632/oncotarget.1652410.18632/oncotarget.16524 ↗
18. 10.1016/j.biopha.2017.09.01910.1016/j.biopha.2017.09.019 ↗
19. 10.18632/oncotarget.994810.18632/oncotarget.9948 ↗
20. 10.1038/cgt.2017.110.1038/cgt.2017.1 ↗
21. 10.1038/bjc.2011.52010.1038/bjc.2011.520 ↗
22. 10.1016/j.cell.2009.02.03810.1016/j.cell.2009.02.038 ↗
23. 10.1074/jbc.M111.25705510.1074/jbc.M111.257055 ↗
24. 10.2217/epi.13.7310.2217/epi.13.73 ↗
25. 10.3727/096504016X1473251078656410.3727/096504016X14732510786564 ↗